Adaptive Nutrition and Exercise Weight Loss (A-NEW) Study
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a single arm phase II study designed to determine the effects of pharmacotherapy and
a remote behavioral weight loss intervention on weight loss in breast cancer survivors who
are overweight or obese, and the impact of successful weight loss on serum biomarkers and gut
microbiome.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
American Institute for Cancer Research Breast Cancer Research Foundation Wellspan-Hopkins Cancer Health Services Research Fund
Treatments:
Bupropion Bupropion hydrochloride, naltrexone hydrochoride drug combination Naltrexone